Success Metrics

Clinical Success Rate
89.5%

Based on 17 completed trials

Completion Rate
89%(17/19)
Active Trials
1(4%)
Results Posted
18%(3 trials)
Terminated
2(8%)

Phase Distribution

Ph phase_2
5
19%
Ph not_applicable
3
12%
Ph phase_3
6
23%
Ph phase_4
6
23%
Ph phase_1
4
15%

Phase Distribution

4

Early Stage

5

Mid Stage

12

Late Stage

Phase Distribution24 total trials
Phase 1Safety & dosage
4(16.7%)
Phase 2Efficacy & side effects
5(20.8%)
Phase 3Large-scale testing
6(25.0%)
Phase 4Post-market surveillance
6(25.0%)
N/ANon-phased studies
3(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

89.5%

17 of 19 finished

Non-Completion Rate

10.5%

2 ended early

Currently Active

1

trials recruiting

Total Trials

26

all time

Status Distribution
Active(2)
Completed(17)
Terminated(2)
Other(5)

Detailed Status

Completed17
unknown5
Terminated2
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
26
Active
1
Success Rate
89.5%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (16.7%)
Phase 25 (20.8%)
Phase 36 (25.0%)
Phase 46 (25.0%)
N/A3 (12.5%)

Trials by Status

unknown519%
terminated28%
completed1765%
active_not_recruiting14%
not_yet_recruiting14%

Recent Activity

Clinical Trials (26)

Showing 20 of 26 trialsScroll for more
NCT05687500Phase 2

Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP)

Active Not Recruiting
NCT00610038Phase 2

Efficacy and Safety Study of Sulfonylureas in Neonatal Diabetes Mellitus

Completed
NCT07221799Phase 1

OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis

Not Yet Recruiting
NCT02375828Phase 3

Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels

Completed
NCT00267683Phase 3

Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes

Terminated
NCT03284463Phase 2

Safety and Efficacy of Glibenclamide Combined With Rt-PA in Acute Cerebral Embolism

Completed
NCT05137678Phase 4

Evaluate the Use of Glibenclamide on Acute aSAH

Unknown
NCT05148403Phase 1

To Evaluate the Effect of Glibenclamide in Reducing Brain Edema of TBI

Unknown
NCT04960657Not Applicable

The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers

Completed
NCT04231617Not Applicable

The Hemodynamic Effects of CGRP After Glibenclamide Administration in Healthy Volunteers

Completed
NCT02318693Phase 4

Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)

Completed
NCT03569540Phase 4

Glibenclamide in Aneurysmatic Subarachnoid Hemorrhage

Unknown
NCT01822548Phase 3

Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes

Completed
NCT02830048Phase 2

Low dosE GlibENclamide in Diabetes Part A

Completed
NCT00393718Phase 3

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Completed
NCT02080377Phase 3

A Feasibility Study Looking at the Use of Glibenclamide and metfoRmin Versus stAndard Care in gEstational diabeteS

Completed
NCT00734669

Risk of Hypoglycemia in Type 2 Diabetes

Completed
NCT02201602Phase 4

Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study

Completed
NCT02145611Phase 4

Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension

Completed
NCT02128022Phase 1

Cardioprotective Effects of GLP-1 and Their Mechanisms

Completed

Drug Details

Intervention Type
DRUG
Total Trials
26